Search for: "MYLAN, INC." Results 541 - 560 of 674
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
13 Jan 2010, 3:00 am
Cobrek Pharmaceuticals, Inc (Patent Docs) Nexium (Esomeprazole) – US: Teva drops patent challenge following settlement agreement with AstraZeneca over Nexium (IP Factor) (GenericsWeb) Nuvigil (Armodafinil) - US: Mylan confirms first-to-file patent challenge relating to sleep-disorder drug (SmartBrief) Nuvigil (Armodafinil) - US: Cephalon sues Watson for patent infringement following Para IV challenge (Patent Docs) (GenericsWeb) (Patentcircle) Tasigna (Nilotinib) - India:… [read post]
23 Dec 2009, 12:40 am
Sandoz Limited (EPLAW) Fuzeon (Enfuvirtide) - US: If there are no sources of proof in the E D of Texas, expect to transferred: In re Hoffman-La Roche Inc (Filewrapper) Gemzar (Gemcitabine) – US: Eli Lilly appeals from grant of partial summary judgment finding certain claims invalid for double patenting: Sun Pharma v Eli Lilly (PATracer) Gemzar (Gemcitabine) – US: Eli Lilly files patent infringement complaint against APP Pharmaceuticals following Para IV challenge (Patent Docs)… [read post]
18 Dec 2009, 9:59 am by Karen E. Keller
Mylan Pharmaceuticals Inc., Mylan, Inc., Matrix Laboratories Ltd. and Matrix Laboratories Inc. [read post]
1 Dec 2009, 9:45 am by Karen E. Keller
Mylan Inc., Matrix Laboratories Limited and Matrix Laboratories, Inc. [read post]
25 Oct 2009, 11:07 am
(Perry) with securities law violations for its failure to report timely under Section 13(d) of the Securities Exchange Act of 1934 its beneficial ownership of more than 5 percent of the outstanding common stock of Mylan Laboratories Inc. [read post]
25 Oct 2009, 3:46 am
Ivax read the Lanham Act broadly; by contrast, Mylan Labs., Inc. v. [read post]
21 Oct 2009, 6:08 pm by mcarzima@imediainc.com
Generic drug maker, Mylan Inc, will pay the U.S government $121 million to settle a civil dispute, started by a whistleblower, involving Medicaid rebates on drug sales from 2000 to 2004. [read post]
21 Oct 2009, 6:08 pm
Generic drug maker, Mylan Inc, will pay the U.S government $121 million to settle a civil dispute, started by a whistleblower, involving Medicaid rebates on drug sales from 2000 to 2004. [read post]
21 Oct 2009, 6:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech)   Products Adderall (Dextroamphetamine, Amphetamine) – US: Shire announces settlement… [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with Sandoz over… [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with Sandoz over… [read post]
18 Oct 2009, 5:42 pm
Teva announced that it has filed a lawsuit against Mylan Pharmaceuticals, Inc., Mylan Inc. and Natco Pharma Ltd. for patent infringement in the [...] [read post]
14 Oct 2009, 7:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com]   Highlights this week included: Angiomax (Bivalirudin) – US: Medicines Company files patent infringement suit against PLIVA, Barr, Teva following Para IV challenge (Patent Docs) (America-Israel Patent Law) (The IP Factor) (GenericsWeb) Humira (Adalimumab) – US: E D Texas find ‘close issue of claim construction’ supports JMOL of no… [read post]